About Metrion
Metrion Biosciences (‘Metrion’) is a UK-based, ion channel focused Contract Research Organisation (CRO) providing high-quality in vitro preclinical drug discovery and safety profiling services. From our headquarters at Granta Park, Cambridge, we support a global customer base with cardiac safety profiling, ion channel drug discovery screening, medicinal chemistry screening support, and neuroscience assay services.
Role Summary
IRCA Group, a global leader in high-quality food ingredients, has signed a lease at Pioneer Group’s new food and beverage incubator, Gastronomica at Colworth Science Park in Bedfordshire.
IRCA has taken 405 sq ft of space in the facility, providing the company with a strong foothold in the UK market. A specialist in chocolate, creams, fillings, fruits, pistachios and decorations, IRCA currently operates 20 production facilities across Europe, the US, and Vietnam, serving customers in more than 100 countries.
Experienced biotech Chair and executive will guide corporate growth and development
Creative Biolabs introduces CAR-T therapy research solutions and webinars to help scientists drive innovation in CAR-T development.
Creative Biolabs, the world's leading biotechnological solutions provider, today announces its new comprehensive portfolio of solutions to accelerate chimeric antigen receptor T-cell (CAR-T) research. Through its industry-leading platforms, expert scientist guidance and educational webinars, Creative Biolabs is dedicated to helping scientists and research organizations solve technical challenges and drive innovation in CAR-T development.
At ImmuONE, our vision is to transform in vitro inhalation safety assessment by providing the best-in-class in vitro models and tailored in vitro services that most accurately predict in vivo outcomes. We have unique capabilities in the development and commercialisation of immunocompetent 2D and 3D in vitro models and assessments and work with the pharmaceutical, consumer product and chemical sectors globally to provide vital data on safety of new products and pharmacology and efficacy of new therapeutics.
Read Marks & Clerks AI Report 2025 here.
Stevenage, UK, 1 December 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the appointment of Paul Thompson PhD as Chief Development Officer (CDO).
We are pleased to share that o2h Discovery has been recognised as the ‘Best Industry Support Partner of the Year’ at the OBN Awards 2025. This achievement reflects the dedication of our exceptional teams and the strong, collaborative partnerships we have built with various innovative biotech and pharma organisations worldwide.
About us
The Francis Crick Institute is Europe’s largest biomedical research institute under one roof. Our world-class scientists and staff collaborate on vital research to help prevent, diagnose and treat illnesses such as cancer, heart disease, infectious diseases and neurodegenerative conditions.